

16 May 2011

Produced by: RBS Equities (Australia) Limited

Alkane Resources

ALK on its way

Buy


Target price
A\$3.01

Price
A\$1.930

Short term (0-60 days)
n/a

Price performance

	(1M)	(3M)	(12M)
Price (A\$)	2.63	1.22	0.31
Absolute (%)	-26.6	58.2	522.6
Rel market (%)	-23.5	63.9	514.8
Rel sector (%)	-20.5	54.3	397.7



Market capitalisation
A\$519.22m (US\$549.95m)

Average (12M) daily turnover
A\$1.77m (US\$1.81m)

Sector: BBG AP Mining
RIC: ALK.AX, ALK AU
Priced A\$1.93 at close 16 May 2011.
Source: Bloomberg

Analysts

Sam Berridge
+61 2 8259 5955
sam.berridge@rbs.com

Lyndon Fagan
lyndon.fagan@rbs.com

Warren Edney
warren.edney@rbs.com

Todd Scott
todd.scott@rbs.com

Phillip Chippindale
phillip.chippindale@rbs.com

RBS Equities (Australia) Limited, ABN
84 002 768 701, AFS Licence 240530
Level 29, RBS Tower, 88 Phillip Street,
Sydney NSW 2000, Australia

<http://research.rbsm.com>

ALK has announced its first MOU for off take of zirconia product. The MOU outlines plans to build a zirconium oxychloride (ZOC) facility, which would allow ALK to capture upside from value adding processes. We expect further MOU announcements in the near term and maintain our high conviction Buy rating.

Key forecasts

	FY09A	FY10A	FY11F	FY12F	FY13F
EBITDA (A\$m)	2.12	7.51	-8.30	-10.0	73.90
Reported net profit (A\$m)	11.00	7.79	-5.39	-8.94	26.40
Normalised net profit (A\$m) ¹	2.30	7.79	-5.39	-8.94	26.40
Normalised EPS (c) ¹	0.85	2.90	-2.00	-3.32	9.83
Normalised EPS growth (%)	n/a	239.0	n/a	65.80	n/a
Dividend per share (c)	0.00	0.00	0.00	0.00	0.00
Dividend yield (%)	0.00	0.00	0.00	0.00	0.00
Normalised PE (x)	226.0	66.70	n/m	n/m	19.60
EV/EBITDA (x)	242.7	68.50	n/m	n/m	11.30
Price/net oper. CF (x)	-1,596	66.80	-81.3	-59.7	10.50
ROIC (%)	5.26	13.40	-14.2	-17.7	20.40

1. Pre non-recurring items and post preference dividends

year to Dec, fully diluted

Accounting standard: GAAP

Source: Company data, RBS forecasts

MOU supports 1Mtpa base case

ALK has signed a JV for development of a ZOC production facility which will take about 50% of planned production from ALK's Dubbo Zirconia Project (DZP). The facility will produce 15-20ktpa of ZOC which represents 7-10% of global supply. Terms and conditions including location, ownership structure and management are to be defined in a heads of agreement, which the company aims to complete by 31 December 2011. We believe the MOU adds further credibility to the development plans of ALK and the viability of its processing flow-sheet.

Why so significant?

In ALK's case we believe the announced MOU is of material significance due to a number of factors. 1) The cope of production from the DZP is limited by zirconia demand. This MOU accounts for 50% of zirconia production based on a 1Mtpa plant. Should subsequent MOUs tally to in-excess of ALK's production intentions, it will bring forward the substantial expansion potential of the company's project. 2) The MOU was signed on the basis of downstream test work validating the quality of ALK's product, which we had highlighted as an area of risk. 3) Although the counterparty to the announcement is not disclosed, we believe the support of ALK's product provides positive read through for the support ALK is likely to receive from strategically-interested entities as it endeavours to secure project finance in 2H CY11.

Investment view – expandable zirconia, rare earth and niobium exposure

We believe this MOU will lead to wider industry interest in future DZP supply. Project value is highly sensitive to plant capacity, which in turn is dependant on global demand of zirconia chemicals. Pre-financial crisis demand growth for zirconia chemicals averaged 11%. Should this rate continue near term, the market would absorb production from one DZP per annum. We see ALK as being well placed to meet this demand going forward.

Important disclosures can be found in the Disclosures Appendix.

Should demand for zirconia chemicals continue at around 10% pa, it would support the expansion of the DZP beyond our base case of 1Mtpa

Value lies in expansion optionality

There is 57% upside to our risk-weighted valuation for ALK on current prices. If we remove the 30% discount we apply to account for development risk, our valuation for ALK increases to A\$4.10, representing a 113% upside base on the last close. However, the real upside to ALK in our view lies in the expansion potential of its deposit. Should demand for zirconia chemicals continue at around 10% pa, it would support the expansion of the DZP beyond our base case of 1Mtpa. Due to its long mine life (75 years), expanding production has a substantial positive impact on our NPV as the value of the resource is brought forward.

Table 1 : ALK sensitivity to DZP expansion

Plant throughput	1Mtpa (RBS base case)	2Mtpa	3Mtpa
capex	400	800	1200
NPV (incl 30% discount)	3.01	5.46	6.74
Mine life (years)	75	37.5	25

Source: RBS forecasts

We acknowledge that considering the upside potential for a plant which is at least six months away from beginning construction may be premature. We also believe that the expansion potential and continuity of long-term supply are relevant in light of recent demand growth in zirconia chemicals and current market tightness.

Zircon, zirconia and zirconium oxychloride

Zircon ($ZrSiO_4$) is the most widely used raw material for zirconia (ZrO_2) chemical production. About 20% of global zircon demand is attributable to downstream zirconia chemicals, which is also the fastest growing source of zircon demand (11% CAGR). It is the zirconia chemical market that ALK is targeting via future production from the DZP. Zirconium oxychloride ($ZrOCl_2 \cdot 8H_2O$) or ZOC, which is about 36% zirconia (ZrO_2) by weight, is used as a precursor for the manufacture of end-use zirconium chemicals (Figure 1 below).

China dominates

Existing ZOC production relies on zircon as the key raw material for downstream zirconium products. China dominates world ZOC supply with about 90% of the 200ktpa market. About 40% of ZOC production is exported with the balance being consumed in China. Recent tightness on zircon markets has flowed into downstream ZOC markets, resulting in both China and non-Chinese customers experiencing difficulty in sourcing supply. ALK's Dubbo Zirconia Project offers the potential for a material quantities of ZOC production not directly linked to zircon or Chinese markets.

ALK's Dubbo Zirconia Project offers the potential for material quantities of ZOC production not directly linked to zircon or Chinese markets

Table 2 : Zircon, zirconia and zirconium


Product	Chemical formula	Produced by	Use	Global demand (ktpa)	Price (US\$/t)
Zirconium	Zr	high end refining	nuclear power plants	5-10	150,000-200,000
zirconia	ZrO ₂	chemical manufactures (ALK from 2013)	multiple chemical applications	200	7,500-8,000
zircon	ZrSiO ₄	miners	tiles	1200	1,600-1,700

Source: Company data

Leveraged to global consumption

Zirconia chemicals are used in a diverse variety of end products in wide number of industries including construction, consumer goods and automotive manufacturing. So there is not one sector zirconia chemical demand is particularly leveraged to. Rather, zirconia demand is a function of increasing global GDP and demand for consumer products.

Figure 1 : Zircon and zirconia end products




Source: TZMI, ALK

Valuation and target price


Our DCF valuation for ALK is unchanged at A\$3.01ps. We base our valuation on developing a 1Mtpa operation at the DZP and first production by 2013. We apply a 30% discount to our DZP valuation to reflect development risk. We do not factor in the development of the Tomingley or McPhillamy gold deposits, and we apply nominal option values for these. Upside risks to our valuation include lower capex and operating costs than we have forecast and higher commodity prices. Downside risks include delays in the finalisation of the DFS, securing project finance and lower commodity prices than we forecast.

ALK – Financial summary

Number of shares (m)	269	Dec Year End	2009A	2010A	2011F	2012F	2013F	2014F	2015F
Market capitalisation (A\$m)	519	NPAT Reported (A\$m)	11.0	7.8	-5.4	-8.9	26.4	168.8	187.3
Enterprise value (A\$m)	500	NPAT Normalised (A\$m)	2.3	7.8	-5.4	-8.9	26.4	168.8	187.3
Enterprise value (US\$m)	505	EPS (A¢)	0.9	2.9	-2.0	-3.3	9.8	62.8	69.6
		CFPS (A¢)	-0.2	-0.8	-2.4	-7.7	-48.1	75.0	73.7
		DPS (A¢)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
		P/E (x)	226.0	66.7	-96.3	-58.1	19.6	3.1	2.8
		P/CF (x)	-1170.9	-232.4	-81.3	-2.5	-4.0	2.6	2.6
		EV/EBITDA (x)	238.4	67.3	-60.9	-50.5	6.8	1.9	1.8
		EPS Growth	n/m	n/m	-169%	66%	-396%	539%	11%
		Yield (%)	0%	0%	0%	0%	0%	0%	0%
		Production	2009A	2010A	2011F	2012F	2013F	2014F	2015F
		Zirconia (kt)	0.00	0.00	0.00	0.00	3.43	12.69	13.72
		LREO (kt)	0.00	0.00	0.00	0.00	0.83	3.05	3.30
		HREO (kt)	0.00	0.00	0.00	0.00	0.25	0.93	1.00
		FeNb (kt)	0.00	0.00	0.00	0.00	0.81	2.98	3.22
		Total (kt)	0.00	0.00	0.00	0.00	5.31	19.65	21.24
		Costs	2009A	2010A	2011F	2012F	2013F	2014F	2015F
		DZP cash cost (A\$/t)	0	0	0	0	146	144	143
		DZP cash cost (US\$/t)	0	0	0	0	137	124	113
		Assumptions	2009A	2010A	2011F	2012F	2013F	2014F	2015F
		Zirconia (US\$/kg)	0.0	3.6	7.5	11.8	12.0	11.2	10.4
		LREO (US\$/kg)	0	28	60	70	50	35	25
		HREO (US\$/kg)	0	56	80	90	70	55	45
		FeNb (US\$/kg)	0	35	35	35	35	35	35
		AUD/USD	0.79	0.92	1.02	1.00	0.94	0.86	0.79
		Profit & Loss (A\$m)	2009A	2010A	2011F	2012F	2013F	2014F	2015F
		Sales revenue	0	0.0	0	0	121	415	439
		Other revenue	4	9.8	0	0	0	0	0
		Total revenue	4	9.8	0	0	121	415	439
		Operating costs	-2	-2.3	-8	-10	-47	-143	-153
		EBITDA	2	7.5	-8	-10	74	272	286
		Depreciation	0	0.0	0	0	-4	-8	-8
		EBIT	2	7.5	-8	-10	70	264	277
		Net interest benefit / (expense)	0	0.3	1	-3	-32	-23	-10
		Pre-tax profit	2	7.8	-8	-13	38	241	268
		Tax benefit / (expense)	0	0.0	2	4	-11	-72	-80
		Profit after tax	2	7.8	-5	-9	26	169	187
		Minorities	0	0.0	0	0	0	0	0
		NPAT (underlying)	2	7.8	-5	-9	26	169	187
		Significant items	9	0.0	0	0	0	0	0
		NPAT (reported)	11	7.8	-5	-9	26	169	187
		Profitability Analysis (%)	2009A	2010A	2011F	2012F	2013F	2014F	2015F
		EBIT margin	n/m	n/m	n/m	n/m	58%	64%	63%
		EBITDA margin	n/m	n/m	n/m	n/m	61%	66%	65%
		Effective tax rate	0%	0%	-30%	-30%	-30%	-30%	-30%
		ROA - EBIT / (total assets - cash)	5%	18%	-20%	-4%	16%	62%	65%
		ROE - NPAT / equity	5%	17%	-9%	-18%	120%	67%	39%
		Cashflow	2009A	2010A	2011F	2012F	2013F	2014F	2015F
		EBITDA	2	8	-8	-10	74	272	286
		Operating cashflow	0	-1	-6	-9	50	210	206
		Capex	-1	0	0	-200	-179	-8	-8
		Free cashflow	-1	-1	-6	-209	-129	202	198
		Investing cashflow	-5	1	0	-200	-179	-8	-8
		Financing cashflow	2	0	21	450	0	-200	-150
		Net Change in cash	-3	0	15	241	-129	2	48
		Balance Sheet Analysis	2009A	2010A	2011F	2012F	2013F	2014F	2015F
		Debt	0	0	0	450	450	250	100
		Equity	44	46	59	50	22	254	478
		Assets	45	47	61	503	556	558	606
		Cash	5	5	19	260	131	133	181
		Net debt	-5	-5	-19	190	319	117	-81
		Gearing - net debt/equity	2009A	2010A	2011F	2012F	2013F	2014F	2015F
		Gearing - net debt/ (net debt + equity)	-12%	-11%	-48%	79%	94%	32%	-20%
		Net debt / EBITDA	-228%	-61%	231%	-1895%	432%	43%	-28%
		EBIT / net interest	9	23	-14	4	-2	-12	-28
		EBITDA / net interest	9	23	-14	4	-2	-12	-29



Sensitivity (US\$m)	NPV(A\$)	2012F	2013F
NPV / NPAT	3.01	-8.9	26.4
zr +10% increase (\$m)	3.20	-8.9	29.5
zr +10% increase (%)	6%	0%	12%
nb +10% increase (\$m)	3.23	-9	29
nb +10% increase (%)	7%	0%	8%
reo +10% increase (\$m)	3.17	-9	30
reo +10% increase (%)	5%	0%	12%
AUD + 10% (\$m)	-0.47	0.00	-7.48
AUD + 10% (%)	-16%	0%	-28%
AUD + 1cent (\$m)	-0.06	0.0	-0.8
AUD + 1cent (%)	-2%	0.0	0.0



Source: Company data, RBS forecasts

Recommendation structure

Absolute performance, short term (trading) recommendation: A Trading Buy recommendation implies upside of 5% or more and a Trading Sell indicates downside of 5% or more. The trading recommendation time horizon is 0-60 days. For Australian coverage, a Trading Buy recommendation implies upside of 5% or more from the suggested entry price range, and a Trading Sell recommendation implies downside of 5% or more from the suggested entry price range. The trading recommendation time horizon is 0-60 days.

Absolute performance, long term (fundamental) recommendation: The recommendation is based on implied upside/downside for the stock from the target price and, except as follows, only reflects capital appreciation. A Buy/Sell implies upside/downside of 10% or more and a Hold less than 10%. For UK-based Investment Funds research, the recommendation structure is not based on upside/downside to the target price. Rather it is the subjective view of the analyst based on an assessment of the resources and track record of the fund management company. For research on Australian listed property trusts (LPT) or real estate investment trusts (REIT), the recommendation is based upon total return, ie, the estimated total return of capital gain, dividends and distributions received for any particular stock over the investment horizon.

Performance parameters and horizon: Given the volatility of share prices and our pre-disposition not to change recommendations frequently, these performance parameters should be interpreted flexibly. Performance in this context only reflects capital appreciation and the horizon is 12 months.

Market or sector view: This view is the responsibility of the strategy team and a relative call on the performance of the market/sector relative to the region. Overweight/Underweight implies upside/downside of 10% or more and Neutral implies less than 10% upside/downside.

Target price: The target price is the level the stock should currently trade at if the market were to accept the analyst's view of the stock and if the necessary catalysts were in place to effect this change in perception within the performance horizon. In this way, therefore, the target price abstracts from the need to take a view on the market or sector. If it is felt that the catalysts are not fully in place to effect a re-rating of the stock to its warranted value, the target price will differ from 'fair' value.

Distribution of recommendations

The tables below show the distribution of recommendations (both long term and trading). The first column displays the distribution of recommendations globally and the second column shows the distribution for the region. Numbers in brackets show the percentage for each category where there is an investment banking relationship. These numbers include recommendations produced by third parties with which RBS has joint ventures or strategic alliances.

Long term recommendations (as at 16 May 2011)

	Global total (IB%)	Asia Pacific total (IB%)
Buy	785 (13)	513 (3)
Hold	410 (7)	222 (1)
Sell	90 (1)	57 (0)
Total (IB%)	1285 (10)	792 (2)

Source: RBS

Trading recommendations (as at 16 May 2011)

	Global total (IB%)	Asia Pacific total (IB%)
Trading Buy	2 (0)	2 (0)
Trading Sell	2 (0)	2 (0)
Total (IB%)	4 (0)	4 (0)


Source: RBS

Valuation and risks to target price

Alkane Resources (RIC: ALK.AX, Rec: Buy, CP: A\$1.930, TP: A\$3.01): We value ALK using a DCF methodology. Upside risks to our target price include production and commodity prices exceeding our expectations. Downside risks include higher-than-forecast capex, commissioning and development delays, and lower-than-forecast commodity prices.

Alkane Resources coverage data

Stock performance, recommendations and coverage (as at 15 May 2011)



Trading recommendation history (as at 16 May 2011)

Date	Rec	Analyst
	n/a	

Source: RBS

Sam Berridge started covering this stock on 3 Mar 11. New recommendation structure from 7 November 2005. Source: RBS

Regulatory disclosures

Global disclaimer

© Copyright 2011 The Royal Bank of Scotland N.V. and affiliated companies ("RBS"). All rights reserved.

This material was prepared by the legal entity named on the cover or inside cover page. It is provided for informational purposes only and does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. While based on information believed to be reliable, no guarantee is given that it is accurate or complete. While we endeavour to update on a reasonable basis the information and opinions contained herein, there may be regulatory, compliance or other reasons that prevent us from doing so. The opinions, forecasts, assumptions, estimates, derived valuations and target price(s) contained in this material are as of the date indicated and are subject to change at any time without prior notice. The investments referred to may not be suitable for the specific investment objectives, financial situation or individual needs of recipients and should not be relied upon in substitution for the exercise of independent judgement. The stated price of any securities mentioned herein is as of the date indicated and is not a representation that any transaction can be effected at this price. Neither RBS nor other persons shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way from the information contained in this material. This material is for the use of intended recipients only and the contents may not be reproduced, redistributed, or copied in whole or in part for any purpose without RBS's prior express consent. In any jurisdiction in which distribution to private/retail customers would require registration or licensing of the distributor which the distributor does not currently have, this document is intended solely for distribution to professional and institutional investors.

Australia: Any report referring to equity securities is distributed in Australia by RBS Equities (Australia) Limited (ABN 84 002 768 701, AFS Licence 240530), a participant of the ASX Group. Any report referring to fixed income securities is distributed in Australia by The Royal Bank of Scotland NV (Australia Branch) (ABN 84 079 478 612, AFS Licence 238266). Australian investors should note that this document was prepared for wholesale investors only.

Canada: The securities mentioned in this material are available only in accordance with applicable securities laws and many not be eligible for sale in all jurisdictions. Persons in Canada requiring further information should contact their own advisors.

EEA: This material constitutes "investment research" for the purposes of the Markets in Financial Instruments Directive and as such contains an objective or independent explanation of the matters contained in the material. Any recommendations contained in this document must not be relied upon as investment advice based on the recipient's personal circumstances. In the event that further clarification is required on the words or phrases used in this material, the recipient is strongly recommended to seek independent legal or financial advice.

Denmark: Royal Bank of Scotland N.V. is authorised and regulated in the Netherlands by De Nederlandsche Bank. In addition, Royal Bank of Scotland N.V. Danish branch is subject to local supervision by Finanstilsynet, The Danish Financial Supervisory Authority.

Hong Kong: This document is being distributed in Hong Kong by, and is attributable to, RBS Asia Limited which is regulated by the Securities and Futures Commission of Hong Kong.

India: Shares traded on stock exchanges within the Republic of India may only be purchased by different categories of resident Indian investors, Foreign Institutional Investors registered with The Securities and Exchange Board of India ("SEBI") or individuals of Indian national origin resident outside India called Non Resident Indians ("NRIs"). Any recipient of this document wanting additional information or to effect any transaction in Indian securities or financial instrument mentioned herein must do so by contacting a representative of RBS Equities (India) Limited. RBS Equities (India) Limited is a subsidiary of The Royal Bank of Scotland N.V..

Italy: Persons in Italy requiring further information should contact The Royal Bank of Scotland N.V. Milan Branch.

Japan: This report is being distributed in Japan by RBS Securities Japan Limited to institutional investors only.

South Korea: This document is being distributed in South Korea by, and is attributable to, RBS Asia Limited (Seoul) Branch which is regulated by the Financial Supervisory Service of South Korea.

Malaysia: RBS research, except for economics and FX research, is not for distribution or transmission into Malaysia.

Netherlands: the Authority for the Financial Markets ("AFM") is the competent supervisor.

Russia: This Material is distributed in the Russian Federation by RBS and "The Royal Bank of Scotland" ZAO (general banking license No. 2594 issued by the Central Bank of the Russian Federation, registered address: building 1, 17 Bolshaya Nikitskaya str., Moscow 125009, the Russian Federation), an affiliate of RBS, for information purposes only and is not an offer to buy or subscribe or otherwise to deal in securities or other financial instruments, or to enter into any legal relations, nor as investment advice or a recommendation with respect to such securities or other financial instruments. This Material does not have regard to the specific investment purposes, financial situation and the particular business needs of any particular recipient. The investments and services contained herein may not be available to persons other than "qualified investors" as this term is defined in the Federal Law "On the Securities Market".

Singapore: Any material in connection with equity securities is distributed in Singapore by The Royal Bank of Scotland Asia Securities (Singapore) Pte Limited ("RBS Asia Securities") (RCB Regn No. 198703346M). Without prejudice to any of the foregoing disclaimers, this material and the securities, investments or other financial instruments referred to herein are not in any way intended for, and will not be available to, investors in Singapore unless they are institutional investors (as defined in Section 4A(1) of the Securities and Futures Act (Cap. 289) of Singapore ("SFA") or relevant persons falling within Section 275 of the SFA and in accordance with the conditions specified therein or otherwise fall within the circumstances under Section 275 of the SFA. Further, without prejudice to any of the foregoing disclaimers, where this material is distributed to accredited investors or expert investors as defined in Regulation 2 of the Financial Advisers Regulations ("FAR") of the Financial Advisers Act (Cap. 110) of Singapore ("FAA"), RBS Asia Securities is exempted by Regulation 35 of the FAR from the requirements in Section 36 of the FAA mandating disclosure of any interest in securities referred to in this material, or in their acquisition or disposal. Recipients who do not fall within the description of persons under Regulation 49 of the Securities and Futures (Licensing and Conduct of Business) Regulations or Regulations 34 and 35 of the Financial Advisers Regulations should seek the advice of their independent financial advisor prior to taking any investment decision based on this document or for any necessary explanation of its contents.

Thailand: Pursuant to an agreement with Asia Plus Securities Public Company Limited (APS), reports on Thai securities published out of Thailand are prepared by APS but distributed outside Thailand by RBS Bank NV and affiliated companies. Responsibility for the views and accuracy expressed in such documents belongs to APS.

Turkey: The Royal Bank of Scotland N.V. is regulated by Banking Regulation and Supervision Authority (BRSA).

UAE and Qatar: This report is produced by The Royal Bank of Scotland N.V. and is being distributed to professional and institutional investors only in the United Arab Emirates and Qatar in accordance with the regulatory requirements governing the distribution of investment research in these jurisdictions.

Dubai International Financial Centre: This material has been prepared by The Royal Bank of Scotland N.V. and is directed at "Professional Clients" as defined by the Dubai Financial Services Authority (DFSA). No other person should act upon it. The financial products and services to which the material relates will only be made available to customers who satisfy the requirements of a "Professional Client". This Document has not been reviewed or approved by the DFSA.

Qatar Financial Centre: This material has been prepared by The Royal Bank of Scotland N.V. and is directed solely at persons who are not "Retail Customer" as defined by the Qatar Financial Centre Regulatory Authority. The financial products and services to which the material relates will only be made available to customers who satisfy the requirements of a "Business Customer" or "Market Counterparty".

United States of America: This document is intended for distribution only to "major institutional investors" as defined in Rule 15a-6 under the U.S. Exchange Act of 1934 as amended (the "Exchange Act"), and may not be furnished to any other person in the United States. Each U.S. major institutional investor that receives these materials by its acceptance hereof represents and agrees that it shall not distribute or provide these materials to any other person. Any U.S. recipient of these materials that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this document, should contact and place orders solely through a registered representative of RBS Securities Inc., 600 Washington Boulevard, Stamford, CT, USA. Telephone: +1 203 897 2700. RBS Securities Inc. is an affiliated broker-dealer registered with the U.S. Securities and Exchange Commission under the Exchange Act, and a member of the Securities Investor Protection Corporation (SIPC) and the Financial Industry Regulatory Authority (FINRA).

- Material means all research information contained in any form including but not limited to hard copy, electronic form, presentations, e-mail, SMS or WAP.

The research analyst or analysts responsible for the content of this research report certify that: (1) the views expressed and attributed to the research analyst or analysts in the research report accurately reflect their personal opinion(s) about the subject securities and issuers and/or other subject matter as appropriate; and, (2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views contained in this research report. On a general basis, the efficacy of recommendations is a factor in the performance appraisals of analysts.

For a discussion of the valuation methodologies used to derive our price targets and the risks that could impede their achievement, please refer to our latest published research on those stocks at research.rbsm.com.

Disclosures regarding companies covered by us can be found on our research website at research.rbsm.com.

Our policy on managing research conflicts of interest can be found at <https://research.rbsm.com/Disclosure/Disclosure.Aspx?MI=2>.

Should you require additional information please contact the relevant research team or the author(s) of this report.